OneSource Specialty Pharma Reports Consolidated Financial Results for Fiscal Year Ending March 31, 2026

OneSource Specialty Pharma Reports Consolidated Financial Results for Fiscal Year Ending March 31, 2026​

OneSource Specialty Pharma Limited today released its financial results for the fiscal year ended March 31, 2026, alongside the corresponding quarterly results. The statement details the consolidated performance and financial standing of the Group, including key figures for the quarter and the full year.

Financial Performance Highlights (Rs. in Million)​

The Group recorded consolidated revenue from operations of Rs. 14,215.90 million for the year ended March 31, 2026. This represented a decrease compared to the Rs. 14,448.53 million reported in the previous year.

Consolidated Profit/(Loss) before tax for the year was (Rs. 738.03) million. The Group's total comprehensive income/(loss) for the fiscal year stood at (Rs. 211.46) million.

The cash flow statement highlights that the Group generated a net cash flow from operating activities of Rs. 85.23 million for the year ended March 31, 2026.

Comparative Financial Results (Years Ended March 31)​

A summary of the key consolidated financial results across the reporting periods is presented below:

Balance Sheet and Asset Position​

The Group's total assets increased to Rs. 82,100.14 million as at March 31, 2026, compared to Rs. 75,502.42 million at the end of the previous year.

The composition of assets shows significant growth in key categories:

• Total Non-current Assets: Increased to Rs. 67,840.74 million (from Rs. 64,640.61 million).
• Total Current Assets: Increased to Rs. 14,259.40 million (from Rs. 10,861.81 million).

In liabilities, total non-current liabilities stood at Rs. 9,367.56 million, while total current liabilities reached Rs. 14,419.69 million.

Segmental Breakdown​

The segment information reveals that CDMO (Contract Development and Manufacturing Organization) remains the primary revenue contributor, reporting a consolidated revenue of Rs. 14,215.90 million for the full year.

Strategic Corporate Updates​

During the financial year, the Group undertook several strategic activities:

1. Amalgamation: The Group approved a Composite Scheme of Arrangement and Amalgamation amongst several subsidiaries, including Stelis Pte. Ltd. and OneSource Specialty Pte. Ltd. The amalgamation was effective from January 1, 2026, under the provisions of the Companies Act, 1967 of Singapore. The transaction was accounted for as a common control transaction and had no material impact on the consolidated financial position.
2. Litigation Claim: Biolexis Pte Limited, a subsidiary of the Group, received a claim from Prestige Biopharma Limited for USD 136.32 million (Rs. 12,862.20 million) during the year ended March 31, 2023, related to the Sputnik Light Vaccine. The Group firmly denies liability for these claims, citing Prestige's lack of manufacturing plant readiness and raw material supply readiness. The matter is currently pending before the Singapore International Arbitration Centre (SIAC).

The Group's financial statements, including the consolidated balance sheet, were compiled from the related audited and reviewed financial statements and were approved by the Board of Directors on May 13, 2026.

ONESOURCE Stock Price Movement​

Today, Onesource Specialty Pharma Limited shares edged higher to close at ₹1855.9, marking a gain of 1.98%. The stock settled on solid investor conviction, posting a total traded volume of 146,531 shares.